Pharmesis International Ltd. (SGX:BFK)
Singapore · Delayed Price · Currency is SGD 0.1250
0.00 (0.00%)
At close: Aug 14, 2026
Pharmesis International Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 28.42 | 43.75 | 67.65 | 45.64 | 50.37 | 52.77 | |
Revenue Growth | -59.97% | -35.32% | 48.24% | -9.40% | -4.55% | 12.01% |
Cost of Revenue | 18.89 | 27.92 | 43.5 | 24.82 | 26.36 | 27.77 |
Gross Profit | 9.53 | 15.84 | 24.15 | 20.82 | 24.01 | 25 |
Selling, General & Admin | 18.36 | 21.15 | 22.13 | 23.61 | 26.54 | 23.94 |
Operating Expenses | 17.86 | 21.15 | 22.13 | 23.61 | 26.54 | 23.94 |
Operating Income | -8.34 | -5.31 | 2.02 | -2.8 | -2.53 | 1.06 |
Interest Expense | -0.61 | -0.68 | -0.7 | -0.87 | -0.94 | -1.04 |
Interest & Investment Income | - | 0.03 | 0 | 0.02 | 0.03 | 0.03 |
Currency Exchange Gain (Loss) | - | - | 0 | 0.05 | - | - |
Other Non Operating Income (Expenses) | 1.97 | 1.97 | 0.19 | -1.26 | 0.28 | 2.06 |
EBT Excluding Unusual Items | -6.98 | -4 | 1.53 | -4.86 | -3.16 | 2.12 |
Asset Writedown | - | - | 6.91 | - | - | - |
Pretax Income | -6.98 | -4 | 8.44 | -4.86 | -3.16 | 2.12 |
Income Tax Expense | 0.31 | 0.31 | 0.83 | 0.05 | 0.02 | 0.15 |
Earnings From Continuing Operations | -7.29 | -4.3 | 7.61 | -4.9 | -3.18 | 1.97 |
Minority Interest in Earnings | - | - | 0.67 | -0.05 | -0.38 | -0.8 |
Net Income | -7.29 | -4.3 | 8.28 | -4.96 | -3.56 | 1.17 |
Net Income to Common | -7.29 | -4.3 | 8.28 | -4.96 | -3.56 | 1.17 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 32 | 32 | 30 | 26 | 23 | 23 |
Shares Outstanding (Diluted) | 32 | 32 | 30 | 26 | 23 | 23 |
Shares Change | -0.05% | 6.13% | 13.08% | 14.85% | - | - |
EPS (Basic) | -0.23 | -0.14 | 0.28 | -0.19 | -0.15 | 0.05 |
EPS (Diluted) | -0.23 | -0.14 | 0.28 | -0.19 | -0.15 | 0.05 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 4.41 | 2.36 | -3.54 | -12.17 | 6.33 | -0.93 |
Free Cash Flow Per Share | 0.14 | 0.07 | -0.12 | -0.46 | 0.28 | -0.04 |
Gross Margin | 33.53% | 36.20% | 35.70% | 45.61% | 47.67% | 47.38% |
Operating Margin | -29.33% | -12.13% | 2.99% | -6.13% | -5.02% | 2.01% |
Profit Margin | -25.65% | -9.83% | 12.24% | -10.86% | -7.07% | 2.22% |
Free Cash Flow Margin | 15.51% | 5.40% | -5.24% | -26.66% | 12.56% | -1.76% |
EBITDA | -6.04 | -3.01 | 3.24 | -1.62 | -1.19 | 2.33 |
EBITDA Margin | -21.26% | -6.89% | 4.78% | -3.54% | -2.36% | 4.42% |
D&A For EBITDA | 2.29 | 2.3 | 1.21 | 1.18 | 1.34 | 1.27 |
EBIT | -8.34 | -5.31 | 2.02 | -2.8 | -2.53 | 1.06 |
EBIT Margin | -29.33% | -12.13% | 2.99% | -6.13% | -5.02% | 2.01% |
Effective Tax Rate | - | - | 9.80% | - | - | 7.04% |